Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference
18 Ottobre 2023 - 7:30AM
Business Wire
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering
clinical-stage biotechnology company which specializes in the
development of novel therapies to restore, treat, and prevent
within the field of hearing loss disorders, is pleased to announce
its participation, in-person, in the European Society of Gene
& Cell Therapy (ESGCT) conference, taking place on
October 24-27, 2023, in Brussels, Belgium.
Laurent Désiré, PhD, Head of Preclinical Development, and Pierre
Rambeau, PhD, Preclinical Scientist, will co-present the poster
entitled “Preclinical development of SENS-501 as a treatment for
the autosomal recessive non-syndromic deafness 9 (DFNB9) using an
adeno associated vector-based gene therapy”, (P011).
The poster sessions will take place on October 25, 2023, from
5pm to 6.15pm CET (11am-12.15pm ET) and on October 26, from 8.30pm
to 9.30pm CET (2.30pm-3.30pm ET).
About Sensorion Sensorion is a pioneering clinical-stage
biotech company, which specializes in the development of novel
therapies to restore, treat and prevent hearing loss disorders, a
significant global unmet medical need. Sensorion has built a unique
R&D technology platform to expand its understanding of the
pathophysiology and etiology of inner ear related diseases,
enabling it to select the best targets and mechanisms of action for
drug candidates. It has two gene therapy programs aimed at
correcting hereditary monogenic forms of deafness, developed in the
framework of its broad strategic collaboration focused on the
genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT)
targets deafness caused by mutations of the gene encoding for
otoferlin and GJB2-GT targets hearing loss related to mutations in
GJB2 gene to potentially address important hearing loss segments in
adults and children. The Company is also working on the
identification of biomarkers to improve diagnosis of these
underserved illnesses. Sensorion’s portfolio also comprises
clinical-stage small molecule programs for the treatment and
prevention of hearing loss disorders. Sensorion’s clinical-stage
portfolio includes one Phase 2 product: SENS-401 (Arazasetron)
progressing in a planned Phase 2 proof of concept clinical study of
SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner
Cochlear Limited, in a study of SENS-401 in patients scheduled for
cochlear implantation. A Phase 2 study of SENS-401 was also
completed in Sudden Sensorineural Hearing Loss (SSNHL) in January
2022. www.sensorion.com
Label: SENSORION ISIN: FR0012596468 Mnemonic:
ALSEN
Disclaimer This press release contains certain
forward-looking statements concerning Sensorion and its business.
Such forward looking statements are based on assumptions that
Sensorion considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the 2022 full year financial report published on March
30, 2023, and available on our website and to the development of
economic conditions, financial markets, and the markets in which
Sensorion operates. The forward-looking statements contained in
this press release are also subject to risks not yet known to
Sensorion or not currently considered material by Sensorion. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance, or achievements of Sensorion to
be materially different from such forward-looking statements. This
press release and the information that it contains do not
constitute an offer to sell or subscribe for, or a solicitation of
an offer to purchase or subscribe for, Sensorion shares in any
country. The communication of this press release in certain
countries may constitute a violation of local laws and regulations.
Any recipient of this press release must inform oneself of any such
local restrictions and comply therewith.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017489817/en/
Investor Relations Noémie Djokovic, Investor Relations
and Communication Associate ir.contact@sensorion-pharma.com
Press Relations Ulysse Communication Pierre-Louis Germain
/ 00 33 (0)6 64 79 97 51 plgermain@ulysse-communication.com
Bruno Arabian / 00 00(0)6 87 88 47 26
barabian@ulysse-communication.com
Grafico Azioni Sensorion (EU:ALSEN)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Sensorion (EU:ALSEN)
Storico
Da Mag 2023 a Mag 2024
